Drug Distribution Industry in China Will Continue to See Consolidation Through 2015
JUN 11, 2012 - 06:08 ET
ROCKVILLE, MD--(Marketwire - June 11, 2012) - MarketResearch.com has announced the addition of the new report "The Pharmaceutical Market: China," to their collection of Pharmaceuticals market reports. For more information, visit http://www.marketresearch.com/Espicom-Healthcare-Intelligence-v1129/Pharmaceutical-China-6974765/
Lowering drug prices remains a top priority for health authorities. The National Development and Reform Commission (NDRC) implemented two rounds of drug price reductions in 2011, one in March and the other in September. Most of the drugs reduced were manufactured by multinationals, which had previously not been subject to pricing controls. In terms of regulatory developments, the SFDA started to inspect overseas manufacturing facilities in November 2011, as the agency seeks to align its practices with international standards. In July 2011, the MoH revealed that it may introduce mandatory licensing policy to secure cheaper drugs for HIV/AIDS patients, as part of the country's universal health coverage programme.
The highly fragmented drug distribution industry in China continued to see consolidation in 2011. This is part of the government's 12th Five-Year Plan 2011-2015, to strengthen the national drug distribution industry by actively supporting acquisitions, mergers and reorganisations. There were a number of competitive strategies completed in the second half of 2011: GPHG acquired Qingdao Likang Pharmaceutical Company and Shandong Hua Wei; Pfizer signed a drug distribution agreement with Jointown; Alliance Boots signed a letter of intent to acquire a stake in Nanjing Pharmaceutical; and Shanghai Pharmaceutical Group strengthened its drug distribution in Northern China through a large capital expenditure.
Espicom projects that the Chinese pharmaceutical market will grow by a moderate double-digit figure between 2012 and 2017. China will be the largest pharmaceutical market in the Asia Pacific region, overtaking Japan in 2016. China will represent over a third of the Asia Pacific region's total pharmaceutical market in 2017. A number of Chinese pharmaceutical manufacturers have witnessed massive growth in recent years and have expanded their operations both domestically and abroad. The top 10 local pharmaceutical manufacturers, including China Pharmaceutical Group, Harbin Pharmaceutical Group, North China Pharmaceutical and Shanghai Pharmaceuticals, had collective revenue of around US$10.0 billion in 2010.
For more information, visit http://www.marketresearch.com/Espicom-Healthcare-Intelligence-v1129/Pharmaceutical-China-6974765/
MarketResearch.com is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, MarketResearch.com offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. Moreover, MarketResearch.com's Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance. For more information, call Veronica Franco at 240-747-3016 or visit http://www.marketresearch.com.
FOR FURTHER INFORMATION PLEASE CONTACT: